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Symptoms of T cell hyperactivation shape the course
andoutcomeofHIV-1 infection, but themechanism(s)
underlying this chronic immuneactivationarenotwell
understood. We find that the viral transactivator Tat
promotes hyperactivation of T cells by blocking the
nicotinamide adenine dinucleotide (NAD+)-depen-
dent deacetylase SIRT1. Tat directly interacts with
the deacetylase domain of SIRT1 and blocks the
ability of SIRT1 to deacetylate lysine 310 in the p65
subunit of NF-kB. Because acetylated p65 is more
active as a transcription factor, Tat hyperactivates
theexpressionofNF-kB-responsivegenes,a function
lost in SIRT1/ cells. These results support amodel
where the normal function of SIRT1 as a negative reg-
ulator of T cell activation is suppressed by Tat during
HIV infection. These events likely contribute to the
state of immune cell hyperactivation found in HIV-
infected individuals.
INTRODUCTION
Immune activation is a hallmark of HIV-1 infection and a signifi-
cant factor that promotes continuous viral replication and
CD4+ T cell depletion (Douek et al., 2003; Fauci et al., 1996;
Lawn et al., 2001). In HIV-infected individuals, levels of circulating
activation markers correlate with accelerated disease progres-
sion and shortened survival. HIV infection is critically dependent
on the activated state of CD4+ T cells since the virus cannot rep-
licate efficiently in resting T cells. Quiescent T cells in blood are
refractory to infection because of blocks at the level of reverse
transcription and proviral integration (Chiu et al., 2005; Steven-
son et al., 1990). In addition, T cell activation enhances viral tran-
scription through the activation of various transcription factors,
notably nuclear factor kB (NF-kB) (Nabel and Baltimore, 1987).
HIV-1 infection itself manipulates the activation status of
infected T cells through the expression of viral proteins, including
Env, Nef, and Tat (Chirmule and Pahwa, 1996; Fackler and Baur,158 Cell Host & Microbe 3, 158–167, March 2008 ª2008 Elsevier In2002; Peruzzi, 2006; Schindler et al., 2006). The viral transactiva-
tor Tat potently activates HIV transcription and binds to an RNA
stem-loop structure termed TAR that spontaneously forms at the
50 extremities of all viral transcripts (Barboric and Peterlin, 2005).
Tat also influences the expression of cellular genes in infected
T cells. For example, Tat synergizes with signals mediated via
the T cell receptor (TCR) and the CD28 coreceptor to superacti-
vate interleukin (IL)-2 gene expression (Fortin et al., 2004; Ott
et al., 1997; Westendorp et al., 1994).
IL-2 is aTcell growth factorwith critical functions in lymphocyte
proliferation, cell survival, and tolerance (Waldmann, 2006). IL-2
expression is dependent on coordinated signals delivered via
the TCR and coreceptors and is tightly regulated at the transcrip-
tional level. IL-2 is important duringHIV infection: it primesnonac-
tivated bystander cells for infection in the absence of antigenic
stimulation (Kinter et al., 1995; Unutmaz et al., 1994). IL-2,
IL-15, and other soluble factors present at lower concentration
in the milieu of lymphoid tissue combine to increase permissive-
ness of naiveCD4+T cells toHIV infection (Kreisberg et al., 2006).
While the function of Tat in viral transcription is well studied,
the molecular mechanism underlying its immunomodulatory ef-
fects is less clear. Many prior reports have linked Tat with altered
NF-kB action (Buonaguro et al., 1994; Cota-Gomez et al., 2002;
Demarchi et al., 1996; Ott et al., 1997, 1998; Scala et al., 1994;
Westendorp et al., 1994, 1995). In addition to its central role in
the regulation of the innate and adaptive immune responses,
NF-kB is a critical regulator of HIV transcription. The HIV-1 long
terminal repeat (LTR) contains two tandem NF-kB binding sites.
The activity of the prototypical NF-kB complex (a heterodimer of
p50 and p65 subunits) is regulated through its association with
inhibitory IkB molecules and through various posttranslational
modifications, including phosphorylation and acetylation. IkB
molecules complexed to the NF-kB dimer in the cytoplasm are
rapidly phosphorylated, polyubiquitylated, and degraded after
T cell activation via the TCR, allowing nuclear translocation
of NF-kB. After translocation, the p65 subunit undergoes post-
translational modifications, including reversible acetylation by
the histone acetyltransferase p300 (Chen et al., 2002; Kiernan
et al., 2003). The acetylation of lysines 218 and 221 enhances
DNA binding and prevents assembly with IkBa and nuclear
export of p65, while acetylation of lysine 310 (K310) potentiatesc.
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Tat Inhibits SIRT1Figure 1. Tat and Nicotinamide Cause T Cell Hyperactivation
(A) Western blot analysis of Tat protein in Jurkat T cells infectedwith lentiviral vectors expressing LTR-GFP and LTR-Tat-GFP. Infected cultures were activated for
2 hr and 8 hr with a-CD3/28 antibodies.
(B) Real-time RT-PCR analysis of IL-2 mRNA levels in infected cultures 2 hr after activation with a-CD3/28. Results are expressed as fold induction by a-CD3/28
treatment.
(C) IL-2 protein levels measured by ELISA in the supernatant of infected cultures 8 hr after a-CD3/28 treatment.
(D) Real-time RT-PCR analysis of IL-2 mRNA levels in noninfected Jurkat T cells after treatment with nicotinamide and activation with a-CD3/28.
(E) Real-time RT-PCR analysis of IL-2 mRNA levels in Jurkat T cells infected with lentiviral vectors after treatment with nicotinamide and activation with a-CD3/28
antibodies.
(F) Western blot analysis of Tat protein in Jurkat T cells infected with lentiviral vectors after treatment with nicotinamide and activation with a-CD3/28. In (B)–(E),
averages of three independent experiments (±SEM) are shown.the transcriptional activity of NF-kB. The transcriptional activity
of NF-kB is suppressed by the deacetylase activities of histone
deacetylase (HDAC)-3 and SIRT1, two proteins that deacetylate
p65 (Chen et al., 2001; Yeung et al., 2004). SIRT1 specifically
deacetylates K310 in p65 and inhibits the antiapoptotic function
of NF-kB (Yeung et al., 2004).
SIRT1 is a mammalian homolog of the yeast transcriptional
repressor silent information regulator 2 (Sir2), an important factor
governing longevity in yeast (Blander and Guarente, 2004). Like
Sir2, SIRT1 requires nicotinamide adenine dinucleotide (NAD+)
as a cofactor, which links its activity to the metabolic state of
the cell. In addition to its enzymatic activity on histone substrates
in vitro, recent experimental evidence suggests that SIRT1 pre-
dominantly targets nonhistone proteins for deacetylation. We re-
cently reported that Tat is a substrate for the deacetylase activity
of SIRT1 (Pagans et al., 2005). Acetylation of lysine 50 (K50) in
Tat is mediated by the histone acetyltransferase activities of
p300 and human GCN5 and generates binding sites for the
bromodomains of PCAF and Brg1 (Agbottah et al., 2006; Col
et al., 2001; Dorr et al., 2002; Kiernan et al., 1999; Mahmoudi
et al., 2006; Mujtaba et al., 2002; Ott et al., 1999). SIRT1 binds
and deacetylates Tat at K50, a process necessary to recycle
nonacetylated Tat protein for binding to TAR RNA and the cellu-
lar positive transcription elongation factor b (P-TEFb).
Because SIRT1 is an important regulator of both NF-kB and
HIV Tat protein, we examined the effects of Tat on the deacety-
lase activity of SIRT1. Our finding that Tat inhibits SIRT1 activity
andpotentiatesNF-kB transcriptional activity unveils amolecular
mechanism by which hyperactivation of immune cells is pro-
moted during HIV infection.CRESULTS
Tat and Nicotinamide Hyperactivate T Cells
via the Same Cellular Pathway
To recapitulate the effect of Tat on immune activation in amanner
as close to natural HIV infection as possible, we employed an
HIV-based lentiviral vector in which both FLAG-tagged Tat and
green fluorescent protein (GFP) are expressed under the control
of the HIV promoter in the 50 LTR. Jurkat T cells were infected
with viral particles containing this vector or a control vector
expressing only GFP. Infected cultures were stimulated with
antibodies specific for the CD3 and CD28 receptors to mimic
physiological T cell activation.
Tat expression was visualized by western blot analysis
(Figure 1A). Treatment with a-CD3/28 slightly increased the
levels of Tat due to the stimulatory effect of these antibodies
on the viral LTR. In cells expressing Tat, an1200-fold induction
of IL-2 mRNA was detected by real-time PCR in response to
a-CD3/28 treatment, whereas IL-2 expression in control cells
was only induced 250 fold (Figure 1B). A similar difference
was observed when IL-2 protein was measured in the culture
supernatant (Figure 1C). No effect of Tat was observed in nonac-
tivated cultures. These findings recapitulated results previously
obtained in peripheral blood lymphocytes and Jurkat T cells
infected with infectious HIV and support a model where Tat syn-
ergistically stimulates IL-2 production following ligation of the
CD3 and CD28 receptors (Fortin et al., 2004; Ott et al., 1997).
To test the potential regulatory role of SIRT1 in the IL-2
response, we treated Jurkat T cells with nicotinamide, a natural
byproduct of the sirtuin deacetylase reaction which functionsell Host & Microbe 3, 158–167, March 2008 ª2008 Elsevier Inc. 159
Cell Host & Microbe
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Treatment with nicotinamide superinduced IL-2 mRNA to similar
levels as Tat in a-CD3/28-stimulated cells (Figure 1D). Superin-
duction of IL-2 mRNA levels was also observed when SIRT1
expression was knocked down in Jurkat T cells via siRNAs (see
Figure S1 available online). To test whether Tat and nicotinamide
synergize in the hyperactivation of IL-2 expression, we treated
Tat- or control-infectedJurkatTcellswithnicotinamidebeforeac-
tivation.Thesestudies revealednoadditiveeffectof combinations
of Tat and nicotinamide on IL-2 expression in a-CD3/28-stimu-
lated T cells (Figure 1E). Levels of Tat protein were equivalent in
infected cultures treated with nicotinamide and control-treated
cultures, excluding the possibility that nicotinamide suppressed
the expression of Tat (Figure 1F). These results suggest that Tat
and nicotinamide may target closely related cellular pathways
and raised the interesting possibility that Tat hyperactivation of
T cells may involve its known assembly with SIRT1.
SIRT1 Is Required for the Hyperactivation
of NF-kB Target Genes by Tat
T cell activation is coupled to the stimulation of several transcrip-
tion factors that regulate the transcriptional status of the IL-2
gene. We focused our efforts on NF-kB since its activity is regu-
lated by SIRT1 (Yeung et al., 2004). We and others previously re-
ported thatTat enhanced IL-2promoteractivity viaNF-kBbinding
sitespresentwithin the IL-2promoter (Fortin et al., 2004;Ott et al.,
1997, 1998;Westendorp et al., 1994).Wespeculated that Tat, like
nicotinamide, inhibits the SIRT1 deacetylase activity leading to
hyperactivation of NF-kB-responsive genes including IL-2.
We tested this hypothesis in mouse embryonic fibroblasts
(MEFs) derived from SIRT1/ mice. MEFs from SIRT1/
and SIRT1+/+ mice were treated with TNFa to induce NF-kB.
Since MEFs do not produce IL-2, we focused instead on the
expression of IkBa, a ubiquitousNF-kB-responsive geneproduct
(Sun et al., 1993). Copy numbers of IkBamRNA were elevated in
SIRT1/ MEFs under basal conditions and in response to
Figure 2. Tat-Mediated Superinduction of NF-
kB-Responsive Genes Requires SIRT1
(A) Western blot analysis of SIRT1, Tat, and b-actin in
SIRT1/MEF cells infected withMSCV-based retro-
viral particles expressing SIRT1 or Tat.
(B–D) Real-time RT-PCR analysis of IkBa (B), E-selec-
tin (C), and GAPDH (D) mRNA levels in the four poly-
clonal MEF populations described in (A) after incuba-
tion with TNFa (20 ng/ml) for 2 hr and 8 hr. Data are
presented relative to values obtained in cells lacking
Tat (100%). The mean of three independent experi-
ments (±SEM) is shown.
TNFa, consistent with the model that SIRT1
suppresses the expression of NF-kB-depen-
dent genes (Figure S2A). Introduction of Tat
via retroviral infection increased endogenous
levels of IkBamRNA5- to 11-fold inSIRT1+/+
MEFs, but only 2- to 3-fold in SIRT1/
MEFs (Figure S2B).
To confirm that Tat-mediated superinduc-
tion of NF-kB-responsive genes was depen-
dent on SIRT1, we reintroduced SIRT1 in SIRT1/ MEFs
via retroviral infection. Polyclonal populations of reconstituted
SIRT1-expressing or SIRT1 null cells were each infected with
retroviral vectors expressing Tat or with the empty vector alone
(Figure 2A). When we examined the induction of IkBa mRNA in
response to TNFa, we found that the presence of Tat increased
the induction of IkBa mRNA 2- to 4-fold over control-infected
cells (Figure 2B). This effect was only observed in cultures where
SIRT1 expression had been reconstituted, demonstrating that
Tat requires SIRT1 expression for the superinduction of the
IkBa gene.
A similar result was observed with E-selectin, another NF-kB-
responsive gene that is also superinduced by Tat (Cota-Gomez
et al., 2002; Lee et al., 2004). After TNFa treatment, endogenous
E-selectin gene expression was enhanced 6-fold by Tat in
SIRT1-expressing, but not in SIRT1-negative cells (Figure 2C).
Here, the Tat effect was only observed at 2 hr after TNFa treat-
ment. At 8 hr, no induction of E-selectin gene expression was
evident, consistent with the prior finding that E-selectin mRNA
accumulation peaks 2 hr after TNFa treatment and then rapidly
declines (Edelstein et al., 2005). In contrast to the results with
IkBa and E-selectin, Tat had no effect on the constitutive expres-
sion of the endogenous glyceraldehyde-3-phosphate dehydro-
genase gene (GAPDH) (Figure 2D).
Tat Neutralizes the Negative Effect of SIRT1
on NF-kB Function
Next, we assessed the effect of Tat on the IkBa and E-selectin
gene promoters. We transfected an IkBa promoter luciferase
reporter construct together with combinations of expression
vectors encoding p65, SIRT1, and Tat into HeLa cells (Figure 3A).
SIRT1 suppressed the activation of the IkBa promoter by p65 in
accordance with the previous finding that deacetylation by
SIRT1 inactivates p65 activity (Yeung et al., 2004). Coexpression
of Tat restored p65 activity, suggesting that Tat interfered with
the deacetylation of p65 by SIRT1 (Figure 3A). No change in160 Cell Host & Microbe 3, 158–167, March 2008 ª2008 Elsevier Inc.
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or Tat (Figure S3). The suppressive activity of SIRT1 was depen-
dent on its intrinsic deacetylase activity, since a catalytically
inactive SIRT1 mutant (P447E; shown in Figure 4D) did not sup-
press the activity of p65 and was unresponsive to the action of
Tat. Expression of Tat did not affect basal or p65-mediated
activity of the IkBa promoter in the absence of SIRT1 expression
(Figure 3A).
The same results were observed using an E-selectin promoter
luciferase construct. Again, SIRT1 reduced p65-activated E-
selectin promoter activity, and Tat reversed the negative effect
of SIRT1 (Figure 3B). No reduction was observed with themutant
SIRT1, which was also unresponsive to Tat (Figure 3B).
To verify that Tat and SIRT1 modulated the activities of the
IkBa and E-selectin promoters through NF-kB, we transfected
p65-, Tat-, and SIRT1-expressing constructs together with
Figure 3. Tat Neutralizes the Inhibitory Effect of SIRT1 onNF-kB-Re-
sponsive Promoters
Promoter reporter assays using (A) the IkBa, (B) the E-selectin, and (C) the 3X-
kB luciferase reporter construct. Luciferase constructs (0.2 mg) were tran-
siently cotransfected with expression vectors for p65 or p65 K310R (1 ng),
SIRT1 or SIRT1 P447E (0.2 mg), and Tat (50 ng) into HeLa cells. The mean of
three independent experiments (±SEM) is shown.Ca 33-kB luciferase reporter containing triple NF-kB binding sites
corresponding to the high affinity IL-2 receptor promoter. Ex-
pression of SIRT1 reduced p65-mediated activation of the 33-
kB reporter, while coexpression of Tat reversed this negative ef-
fect (Figure 3C). Again, expression of the catalytically inactive
SIRT1 mutant did not interfere with the activity of p65, and addi-
tional Tat expression had no effect in this setting (Figure 3C).
Likewise, overexpression of a p65 mutant (K310R), which lacked
the deacetylation site for SIRT1 and showed reduced activation
of the 33-kB reporter, was unaffected by SIRT1 and Tat
(Figure 3C). These results demonstrate that Tat targets the
SIRT1 deacetylase activity to hyperactivate NF-kB function.
Tat Binds the Deacetylase Domain of SIRT1
We showed previously that Tat and SIRT1 interact in cells (Pa-
gans et al., 2005). To map the Tat-interacting domain in SIRT1,
we used deletion mutants of the murine SIRT1 protein (Sir2a)
(Fulco et al., 2003). Progressive N-terminal deletions at amino
acids 120, 236, or 341 did not affect coimmunoprecipitation of
SIRT1 with Tat (Figure 4A, lanes 1–3). However, deletion of the
first 512 amino acids abrogated binding to Tat, indicating that
the Tat-interaction domain lies between amino acids 341 and
512 of SIRT1 (Figure 4A, lane 4). In agreement with this conclu-
sion, expression of amino acids 236 to 510 of SIRT1 proved suf-
ficient to support interaction with Tat (Figure 4A, lane 5). The re-
sults of the coimmunoprecipitation studies are summarized in
Figure 4B.
The region spanning amino acids 341–512 contains the cata-
lytic domain of SIRT1, which is shared among all sirtuins. It is
98% conserved in the murine and human SIRT1 proteins and
consists of two distinct domains: a large Rossmann fold domain
characteristic of NAD+-binding proteins and a smaller domain
containing a structural zinc ion. The NAD+ and acetyl-lysine sub-
strate bind in the active site cleft between the two domains (Ava-
los et al., 2002). To determine whether Tat interacts with the cat-
alytic domain of SIRT1, point mutations were introduced into
human SIRT1 expression construct to disrupt NAD+-binding
(R274A, N346A) or acetyl-lysine binding (F414D, E416A,
V445E, P447E) (Figure 4C). In addition, we mutated two con-
served cysteines (C371/374G) located in a zinc-bound domain
predicted to serve as a protein-protein interaction domain (Min
et al., 2001).
Prior to analyzing their interaction with Tat, the catalytic activ-
ities of these mutants were measured using an in vitro HDAC
assay and radioactive acetylated histone peptides as sub-
strates. We transfected wild-type and mutant SIRT1 proteins
into 293 cells and immunoprecipitated the FLAG-tagged pro-
teins (Figure 4D). The immunoprecipitated material was tested
for enzymatic activity. Incubation with wild-type SIRT1 or the
R274A mutant resulted in deacetylation of the histone peptide
in the presence of NAD+ (Figure 4D). The deacetylase activity
of the F414D, E416A, and V445Emutants was severely impaired,
while no activity was measured for N346A, C371/374G, and
P447E mutants.
Next, we cotransfected wild-type and SIRT1 mutants together
with T7-tagged Tat. Wild-type and mutant SIRT1 proteins were
expressed at similar levels (Figure 4E, upper panel). After pull-
down with T7-agarose, immunoprecipitated complexes were
analyzed for the presence of SIRT1 (Figure 4E, lower panels).ell Host & Microbe 3, 158–167, March 2008 ª2008 Elsevier Inc. 161
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Tat Inhibits SIRT1Figure 4. Tat Binds to the Acetyl Lysine-Binding Site in SIRT1
(A) Coimmunoprecipitation assay of Tat and SIRT1 deletion mutants. Expression vectors for Myc-tagged murine Sir2a deletion mutants or full length human
SIRT1 (each 1 mg) were transiently cotransfected with constructs expressing FLAG-tagged Tat (1 mg) in 293 cells. Immunoprecipitations were performed with
a-FLAG agarose and western blotting with a-Myc and a-FLAG antibodies.
(B) Schematic summary of Tat binding to murine Sir2a deletion mutants. The relative localization of the human SIRT1 HDAC domain is shown at the bottom.
(C) Schematic representation of the human SIRT1 HDAC domain with point mutations.
(D) In vitro HDAC assays of immunoprecipitated human SIRT1 mutants with and without NAD+.
(E) Coimmunoprecipitation of SIRT1 mutants and Tat in 293 cells. Cell extracts were immunoprecipitated with a-T7 agarose followed by western blotting with
a-FLAG and a-T7 antibodies.While binding to Tat was preserved in SIRT1 R274A, N346A,
C371/374G, and E416A, no binding to Tat was observed with
any of the SIRT1 mutants carrying a mutation within the acetyl-
lysine-binding domain (F414D, V445E, and P447E). The same
results were obtained when SIRT1 proteins were immunoprecip-
itated, and coimmunoprecipitation of Tat was determined (data
not shown). These data demonstrate that Tat interacts with the
substrate-binding domain of SIRT1.
Tat Inhibits the SIRT1 Deacetylase Activity
and Induces Hyperacetylation of NF-kB
Since an intact acetyl-lysine binding function is critical for the
deacetylase activity of SIRT1, we tested whether Tat binding
affected the enzymatic activity of SIRT1. We performed fluores-
cent deacetylation assays using purified full-length SIRT1 and
acetylated p53 peptides (aa 379–382). Addition of synthetic Tat
(aa 1–72) inhibited deacetylation of p53 by SIRT1 in a dose-
dependent manner (Figure 5A). The Tat concentration required
for half maximal inhibition (IC50) of SIRT1 was 3.5 ± 0.5 mM. In
contrast, the IC50 for nicotinamide in the same experiments
was 208 ± 21 mM (data not shown). This result indicates that
Tat is a very potent inhibitor of the SIRT1 deacetylase activity.
Next, we examined the effect of Tat on deacetylation of p65. In
vitro acetylated recombinant p65 protein was incubated with
recombinant SIRT1 and synthetic Tat proteins. The extent of
deacetylation was determined by western blotting with an anti-
body specific for acetylated K310 in p65 (a-AcK310 p65).
SIRT1 deacetylated p65 in the absence of Tat (Figure 5B, lane
2). In the presence of Tat, deacetylation of p65 by SIRT1 was
suppressed, confirming that direct interaction between Tat and162 Cell Host & Microbe 3, 158–167, March 2008 ª2008 Elsevier IncSIRT1 inhibits the deacetylase activity of SIRT1 (Figure 5B,
lane 3). The same inhibition of p65 deacetylation by SIRT1 was
observed with nicotinamide (Figure 5B, lane 4).
To test the effect of Tat on p65 acetylation in cells, we trans-
fected expression vectors for p65, p300, SIRT1, and Tat into
293 cells. Overexpressed p65 translocates spontaneously into
the cell nucleus because of limiting amounts of cellular IkBa.
To induce efficient p65 acetylation, we coexpressed the acetyl-
transferase p300 (Figure 5C, lane 2). Coexpression of SIRT1
reduced acetylation of p65 at K310 caused by p300 as expected
(Figure 5C, lane 3). Introduction of Tat restored p65 acetylation in
a dose-response manner (Figure 5C, lane 4–6). These results
demonstrate that Tat reverts deacetylation of p65 by SIRT1 in
cells and induces relative hyperacetylation of p65 in the pres-
ence of SIRT1.
We also examined the acetylation status of endogenous p65 in
Tat-expressing cells. 293 cells were transfected with the Tat
expression vector and treated with TNFa to induce nuclear
translocation of endogenous p65. Acetylation of endogenous
p65 was slightly (1.5-fold) increased in the presence of Tat (Fig-
ure 5D, lane 2). A similar increase was observed when p300 was
overexpressed (Figure 5D, lane 3). Coexpression of p300 and Tat
strongly induced hyperacetylation of endogenous p65 (2.5-fold),
consistent with the model that Tat inhibits physiological deace-
tylation of NF-kB by SIRT1 (Figure 5D, lane 4).
Tat Induces T Cell Hyperactivation through
Hyperacetylation of NF-kB
To examine whether the functions of Tat in SIRT1 inhibition and
T cell hyperactivation are linked, we searched for Tat mutants.
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Tat Inhibits SIRT1Figure 5. Tat Inhibits the SIRT1 Deacetylase
Activity
(A) In vitro deacetylation assay of recombinant
SIRT1 in the presence of synthetic Tat (aa 1–72).
The rate of 1 mM SIRT1 was calculated for
200 mM fluorogenic deacetylase substrate (aa
379–382 of p53) in the presence of twelve concen-
trations of synthetic Tat. The data were plotted in
Prism with X equal to Log10[Tat (mM)] and Y equal
to rate. A nonlinear regression was done using the
one site competitive binding equation to deter-
mine the IC50.
(B) In vitro deacetylase assay of recombinant
SIRT1 and recombinant acetylated p65 in the
presence of synthetic Tat or nicotinamide. West-
ern blotting was performed with a-AcK310 p65
and a-p65 antibodies.
(C) In vivo acetylation assay of overexpressed p65.
Expression vectors encoding T7-tagged p65 (0.5
mg), p300 (2 mg), SIRT1 (1 mg), and Tat (0.1, 0.25,
and 0.5 mg) were transiently cotransfected in 293
cells as indicated. Total cell lysates were analyzed
by Western blotting with a-AcK310 p65, a-T7, and
a-FLAG antibodies. p300 was immunoprecipi-
tated and subjected to western blotting with a-
HA antibody.
(D) In vivo acetylation assay of endogenous p65. 293 cells were cotransfected with expression vectors encoding Tat (0.5 mg) and p300 (10 mg) as indicated and
treated with TNFa (20 ng/ml) and trichostatin (TSA; 400 nM) overnight. TSA is an inhibitor of class I and II HDACs, but not sirtuins, and was added to prolong
nuclear retention of p65 through hyperacetylation of K218 and K221. Endogenous p65 was immunoprecipitated using a-p65 antibody and subjected to western
blotting with a-AcK310 p65 or a-p65 antibodies. Western blotting for p300 was performed with a-HA antibody.deficient in the induction of p65 hyperacetylation. We screened
a series of Tat proteins carrying point mutations in different pro-
tein domains of Tat. These point mutants were expressed in 293
cells together with p65 and the p300 acetyltransferase. Expres-
sion of p300 induced acetylation of K310 in p65, and wild-type
Tat (aa 1–101) further enhanced this acetylation (Figure 6A, lanes
1–3). Mutations within the so-called cysteine-rich and core do-
mains of Tat (C22G, F38A, K41A)markedly decreased hyperace-
tylation of p65 induced by Tat, while a point mutation introduced
into the N-terminal acidic domain (H13L) still hyperacetylated
p65 albeit to a lesser extent (Figure 6A, lanes 4–7). A Tat mutant
containing two point mutations within the RNA-binding domain
(K50/51A) induced p65 hyperacetylation as efficiently as the
wild-type protein (Figure 6A, lane 8). Western blotting with
FLAG antibody showed that wild-type and H13L Tat were
equally expressed while the other Tat mutants were slightly
less expressed (Figure 6A, lower panel). Of note, expression
levels of K41A and K50/51A Tat were equivalent, and both
mutants produced similar effects on acetylation of endogenous
p65 as observed with overexpressed protein (Figure S4). These
mutants were chosen for further analysis.
To study the effect of Tat mutations on T cell activation, we
generated lentiviral vectors expressing wild-type or mutant Tat
proteins (K41A and K50/51A Tat). Because both Tat mutants
have reduced transcriptional activities on the HIV LTR, we chose
a lentiviral construct, which contained the heterologous elonga-
tion factor 1a (EF-1a) promoter driving Tat and GFP expression
instead of the HIV LTR. High titer viral stocks were produced
and used to infect Jurkat T cells. Flow cytometry of GFP showed
equivalent infection with wild-type or mutant Tat-expressing
viruses (Figure 6B). Following treatment with a-CD3/28 anti-
bodies, IL-2 mRNA levels were superinduced 2- to 3-fold byCwild-type Tat (Figure 6C). No superinduction was observed
with K41A Tat while K50/51A Tat superinduced IL-2mRNA levels
as efficiently as wild-type Tat (Figure 6C). These results collec-
tively demonstrate that Tat expressed in the context of lentiviral
infection hyperactivates T cells through hyperacetylation of p65.
DISCUSSION
Our finding that Tat inactivates cellular SIRT1 provides a molec-
ular mechanism responsible for Tat-mediated T cell hyperactiva-
tion. These studies also reveal a unique role for SIRT1 in T cell
activation.
We find that Tat binds to the SIRT1 catalytic site and impairs
the ability of SIRT1 to deacetylate K310 in p65. Consistent with
previous data that deacetylation by SIRT1 inactivates p65 func-
tion, we find NF-kB activity ‘‘superactivated’’ in the presence
of Tat. Based on these results, we propose a model where Tat
hyperactivates T cells through inhibition of SIRT1 and abnormally
sustained action of NF-kB. In the absence of Tat, a balance of
p300 and SIRT1 activities regulates p65 acetylation. This bal-
ance tightly controls the activation of cellular genes involved in
the immune response of T cells (Figure 7A). During HIV infection,
Tat expression disrupts the balance between p300 and SIRT1
and increases levels of acetylated p65 through inhibition of
SIRT1 (Figure 7B). This increase hyperactivates the function of
NF-kB and the expression of NF-kB-responsive genes including
IL-2.
One of the most studied NF-kB-responsive genes is HIV itself.
The two NF-kB binding sites in the HIV enhancer link HIV tran-
scription to the activation status of the infected T cells. This is
particularly important at the beginning of the infectious process
and during reactivation from latency when Tat levels are limiting.ell Host & Microbe 3, 158–167, March 2008 ª2008 Elsevier Inc. 163
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most importantly NF-kB, is essential for the production of full-
length viral transcripts necessary for the initial synthesis of Tat.
Once Tat accumulates to sufficient levels, it binds to TAR RNA
and dramatically increases the elongation competence of the
RNA polymerase II complex through recruitment of the P-TEFb
complex. At that time, Tat may also enhance NF-kB function
through inhibition of SIRT1 (Figure 7B).
Tat itself is deacetylated by SIRT1. Although SIRT1 is a nega-
tive regulator of NF-kB, it functions as a coactivator of Tat trans-
activation through deacetylation of K50 (Pagans et al., 2005).
We favor the model that deacetylation of Tat occurs early in
the infectious process and recycles acetylated Tat to the unace-
tylated form, which is the only form of Tat able to engage in the
formation of the Tat/TAR/P-TEFb complex. Interestingly, in vitro
binding of Tat to SIRT1 does not require acetylation of K50 (Pa-
gans et al., 2005). Accordingly, we show that hyperacetylation of
p65 and T cell hyperactivation are efficiently induced by a Tat
mutant that lacks an intact acetylation site at position 50 (K50/
51A Tat). This raises the possibility that Tat acts as a ‘‘supersub-
strate’’ of the SIRT1 enzymatic activity (Borgstrom, 1975). Acet-
ylated Tat is efficiently deacetylated by SIRT1, but remains
bound to SIRT1 and blocks access of other substrates to the cat-
alytically active site.
We identified Tat mutants (C22G, F38A, and K41A) that no
longer induce p65 hyperacetylation. The finding that one of these
mutants (K41A) also lost its ability to hyperactivate T cells cou-
Figure 6. Hyperacetylation of p65 by Tat Con-
tributes to T Cell Hyperactivation
(A) Induction of p65 hyperacetylation by wild-type and
mutant Tat. Expression vectors encoding T7-tagged
p65 (0.5 mg), p300 (2 mg), wild-type, and mutant Tat
(1 mg each) were transiently cotransfected in 293 cells
as indicated. Immunoprecipitations were performed
with a-T7 agarose or a-FLAG agarose to isolate p65
or Tat followed by western blotting with a-AcK310
p65, a-T7, and a-FLAG antibodies. p300was immuno-
precipitated and subjected to western blotting with a-
HA antibody.
(B) Flow cytometry of Jurkat T cells infected with lenti-
viral vectors expressing wild-type or mutant Tat and
GFP. Data are representative of three independent ex-
periments in which infection efficiencies ranged from
75%–85% GFP+ cells.
(C) Real-time RT-PCR analysis of IL-2 mRNA levels
induced in infected Jurkat T cells after activation with
a-CD3/28 antibodies. Data are presented as fold
induction by a-CD3/28 treatment relative to vector
(EF-1a-GFP)-infected cells (100%). The average
(mean ± SEM) of three independent experiments
is shown.
ples the inhibitory function of Tat on SIRT1
with its role in T cell hyperactivation. Interest-
ingly, C22G, F38A, and K41A Tat mutants
are deficient in the transactivation of the
HIV LTR. This raises the possibility that Tat-
mediated hyperacetylation of p65 may be
part of the activatory function of Tat on the
HIV promoter. However, other Tat mutations
(H13L and K50/51A) also reduce Tat function on the LTR but
maintain the ability of Tat to induce p65 hyperacetylation (Emi-
liani et al., 1998; Ott et al., 1999). C22G, F38A, and K41A muta-
tions lie in the transactivation domain of Tat, which mediates in-
teraction of Tat with the cofactor cyclinT1 (Rice and Carlotti,
1990; Wei et al., 1998). The finding that Tat hyperactivates NF-
kB activity in murine cells makes a direct involvement of cyclin
T1 in Tat-mediated T cell hyperactivation unlikely since murine
cyclin T1 cannot properly bind Tat (Bieniasz et al., 1998; Garber
et al., 1998). However, the fact that both Tat and p65 bind cy-
clinT1 as well as SIRT1 is striking and could indicate that P-
TEFb is somehow involved in this process (Barboric et al.,
2001; Pagans et al., 2005; Yeung et al., 2004).
SIRT1 targets many transcriptional activators in addition to
p65, including p53, Forkhead transcription factors (FOXO1, 3a,
and 4), as well as transcriptional coactivators PGC-1a, PCAF,
and p300 (Sauve et al., 2006). The observation that Tat inhibits
a central regulator of the function of many transcription factors
and transcriptional coactivators provides an explanation of
Tat’s reported pleiotropism. However, these observations raise
a number of additional questions. One remaining question con-
cerns the role of the second exon of the tat gene in T cell hyper-
activation. We and others have previously reported that only the
101-amino acid Tat protein encoded by both tat exons induces
T cell hyperactivation, while the shorter 72-amino acid one-
exon Tat variant does not (Ott et al., 1997; Westendorp et al.,
1994). Our data show that Tat72 effectively blocks the SIRT1164 Cell Host & Microbe 3, 158–167, March 2008 ª2008 Elsevier Inc.
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tivating domain of Tat shared by Tat101 and Tat72 with the hy-
peracetylation of p65 and T cell hyperactivation. We have ob-
served that Tat72 is markedly less expressed in infected T
cells than Tat101 (H.-S.K. and M.O., unpublished data). Future
studies will investigate whether this difference in expression
may account for the different in vivo functions of the two Tat var-
iants or whether residues in the C terminus of Tat101 are also in-
volved in this process.
T cell activation is ahighly controlled processand involvespos-
itive and negative regulatory mechanisms. Our results showing
that inhibition of SIRT1 by Tat and nicotinamide lead to T cell hy-
peractivation identify SIRT1 as a negative regulator of T cell acti-
vation. This concept is supported by our preliminary findings that
SIRT1 protein levels are upregulated after activation of human
primary CD4+ T cells (H.-S.K. and M.O., unpublished data).
This upregulation occurs rather late after activation and may
serve to ‘‘terminate’’ NF-kB function through p65 deacetylation.
T cell activation is dysregulated during the immune hyperacti-
vation syndrome present in individuals infected with HIV-1.
Increased production of proinflammatory cytokines is found in
circulating blood lymphocytes as well as in T cells isolated
from lymphoid tissue (Fauci et al., 1996). Many of these cyto-
kines are regulated by NF-kB and are dysregulated by Tat (Buo-
naguro et al., 1994; Scala et al., 1994). Tat-mediated inhibition of
the SIRT1 deacetylase and the resulting hyperactivation of NF-
kB function may thereby directly participate in the immune dys-
functions in infected patients. While the interaction of Tat with
SIRT1 and NF-kB is likely restricted to infected cells, the result-
ing increased production of proinflammatory cytokines dysregu-
lates neighboring uninfected and infected immune cells. In addi-
tion, Tat and Nef open reading frames are transcribed from
nonintegrated viral cDNAs after infection of quiescent T cells
and cooperate in the induction of T cell activation and chromo-
somal integration of the provirus (Wu and Marsh, 2001).
We speculate that the stimulatory role of Tat may be important
in the very early stages of infection when few CD4+ T cells in
Figure 7. Tat Blocks the SIRT1 Deacetylase Activity and Superin-
duces T Cell Activation and HIV Transcription via NF-kB
(A and B) See text for details.Clymph nodes of patients are activated and infected. This stimu-
latory role is likely to cooperate with proenhancing effects of
Nef on TCR and CD28-mediated signals (Fenard et al., 2005;
Schindler et al., 2006; Wang et al., 2000). Interestingly, elevated
levels of IL-2 are present in lymph nodes of patients early after
infection (Gray et al., 1996; Graziosi et al., 1996). At this time,
the stimulatory effect of Tat may contribute to priming naive
T cells for HIV infection and creating a permissive environment
for the unrestricted propagation of the infectious process
(Li et al., 1997).
The finding that Tat induces T cell hyperactivation through
inhibition of SIRT1 opens the possibility for therapeutic interven-
tion. The role of yeast Sir2 and possibly human SIRT1 in lifespan
extension has fueled the search for sirtuin activators (Baur and
Sinclair, 2006). Activation of SIRT1 might counterbalance Tat-
induced T cell hyperactivation, thus, leading to the possibility
of including activators of the SIRT1 deacetylase activity into
the therapeutic regimen of HIV-infected individuals.
EXPERIMENTAL PROCEDURES
Cells and Plasmids
HeLa, 293, 293T, and Jurkat T cells were cultured under standard tissue
culture conditions. MEF cells derived from SIRT1/ cells were grown as
described (Pagans et al., 2005). Mutant constructs for SIRT1 HDAC domain
were prepared by site-directed mutagenesis using FLAG-tagged SIRT1 as
a template. The Sir2a deletion constructs were kindly provided by V. Sartorelli,
NIH, the 3X-kB luciferase reporter was kindly provided by N. Chirmule, Merck
Inc., the IkBa luciferase reporter was kindly provided by K. Yamamoto, UCSF,
the E-selectin luciferase reporter was kindly provided by J. Pober, Yale Univer-
sity, and the 63 histidine-tagged SIRT1 plasmid was kindly provided by
D. Sinclair, Harvard University.
Infection with Lentiviral Vectors
LTR-GFP and LTR-Tat-GFP are HIV-based vectors derived from the pHR0
series, in which GFP alone or Tat (101 aa) and GFP are under the control of
the HIV-1 LTR through the use of an internal ribosomal entry site (Jordan
et al., 2001). For experiments with mutant Tat, the EF-1a promoter was
inserted into the LTR-GFP vector upstream of wild-type or mutant Tat
(EF1a-Tat-GFP). Details for viral production and infection are described in
the Supplemental Experimental Procedures. Flow cytometry analysis of GFP
expression (FACSCalibur, BD Bioscience) showed that infection efficiencies
ranged from 70%–98% GFP+ cells in individual experiments.
Generation of SIRT1- and Tat-Expressing MEF Cell Lines
Open reading frames corresponding to Myc-tagged human SIRT1 and T7-
tagged HIV-1 Tat (101 aa) were inserted into the murine stem cell virus
(MSCV)-based retroviral vectors MSCV-puromycin and MSCV-zeocin, re-
spectively (Clontech). Details for viral production and infection are described
in the Supplemental Experimental Procedures.
RNA Purification, cDNA Synthesis, and Real-Time RT-PCR
Total RNA was extracted using RNA STAT-60 reagent (Tel-Test) according to
the manufacturer’s instruction. The first strand cDNA was generated using
2 mg of total RNA and SuperScript reverse transcriptase (Invitrogen). Relative
gene expression ratios between stimulated and nonstimulated conditions
were calculated by the equation, ratio = 2DDCt, comparative Ct method (Ap-
plied Biosystems). Details are described in the Supplemental Experimental
Procedures.
Transfections and Coimmunoprecipitations
Luciferase reporter constructs and protein expression vectors were transiently
cotransfected into HeLa cells using Lipofectamine (Invitrogen). Twenty-four
hours after transfection, cells were lysed and processed for luciferase assays
(Promega). p values (paired t test) were used for statistical analysis.ell Host & Microbe 3, 158–167, March 2008 ª2008 Elsevier Inc. 165
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Tat Inhibits SIRT1293 cells grown in 6-well plates at 70% confluence were cotransfected with
expression vectors indicated in the figure legends. Transfection, cell lysis,
immunoprecipitation, and western blotting were previously described (Pagans
et al., 2005). The acetylated p65 protein was quantified using the ImageJ
software available at http://rsb.info.nih.gov/ij.
Fluorescent Deacetylase Assay
Full-length human 63 histidine-tagged SIRT1 was purified using Ni-NTA
agarose (QIAGEN) and Superdex 200 gel filtration. The rate of 1 mM SIRT1
was calculated for 200 mM fluorogenic deacetylase substrate (BioMol) in the
presence of 12 concentrations (1, 2, 3, 4, 5, 6, 10, 15, 25, 50, 126, and
252 mM) of synthetic Tat (72 aa; Peptide Specialty Laboratory, Heidelberg,
Germany). Details of IC50 calculations are described in the Supplemental
Experimental Procedures.
Radioactive HDAC Assays
Expression plasmids for FLAG-tagged wild-type and mutants SIRT1 (1 mg)
were transfected in 293 cells with lipofectamine reagent. Equal amounts of
whole cell extracts (2 mg) were immunoprecipitated and in vitro HDAC assays
were performed as previously described (Pagans et al., 2005).
Recombinant p65 protein was prepared as previously described (Chen
et al., 2005) and used for HDAC assay with recombinant SIRT1 and synthetic
Tat proteins. Details are described in the Supplemental Experimental Proce-
dures.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures and
four supplemental figures and can be found with this article online at http://
www.cellhostandmicrobe.com/cgi/content/full/3/3/158/DC1/.
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